Pyxis oncology announces portfolio prioritization, focusing resources on its lead clinical program, PYX-201

CStone announces first patient enrolled in the global multicenter phase 1b clinical trial of CS5001...

Biocytogen announces Adcendo ApS exercises antibody option to accelerate ADC development

MediLink announces YL201 granted orphan-drug designation by the US FDA

FDA grants breakthrough therapy designation to sacituzumab govitecan for second-line ES-SCLC

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell...